NASDAQ:BLCM - Bellicum Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bellicum Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $10.42 +0.40 (+3.99 %) (As of 02/16/2020 02:31 PM ET) Add Today's Range$10.10Now: $10.42▼$10.9850-Day Range$1.11MA: $3.13▼$11.3552-Week Range$7.21Now: $10.42▼$41.40Volume202,881 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:BLCM Previous Symbol CUSIPN/A CIK1358403 WebN/A PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees173 Outstanding SharesN/AMarket CapN/A Next Earnings Date3/10/2020 (Estimated) OptionableOptionable Receive BLCM News and Ratings via Email Sign-up to receive the latest news and ratings for BLCM and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:BLCM Rates by TradingView Bellicum Pharmaceuticals (NASDAQ:BLCM) Frequently Asked Questions What is Bellicum Pharmaceuticals' stock symbol? Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM." When did Bellicum Pharmaceuticals' stock split? How did Bellicum Pharmaceuticals' stock split work? Bellicum Pharmaceuticals shares reverse split before market open on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 5th 2020. An investor that had 100 shares of Bellicum Pharmaceuticals stock prior to the reverse split would have 10 shares after the split. How were Bellicum Pharmaceuticals' earnings last quarter? Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) posted its quarterly earnings results on Monday, August, 5th. The biopharmaceutical company reported ($5.80) earnings per share for the quarter, missing the Zacks' consensus estimate of ($5.40) by $0.40. The biopharmaceutical company had revenue of $1.39 million for the quarter, compared to the consensus estimate of $0.23 million. View Bellicum Pharmaceuticals' Earnings History. When is Bellicum Pharmaceuticals' next earnings date? Bellicum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Bellicum Pharmaceuticals. Has Bellicum Pharmaceuticals been receiving favorable news coverage? News articles about BLCM stock have trended neutral this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Bellicum Pharmaceuticals earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Bellicum Pharmaceuticals. What other stocks do shareholders of Bellicum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), Cyberark Software (CYBR), TransEnterix (TRXC), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), FireEye (FEYE) and ACADIA Pharmaceuticals (ACAD). Who are Bellicum Pharmaceuticals' key executives? Bellicum Pharmaceuticals' management team includes the folowing people: Mr. Richard A. Fair, Pres, CEO & Director (Age 50)Dr. Alan K. Smith, Exec. VP of Technical Operations (Age 61)Mr. Thomas J. Farrell, Consultant (Age 56)Mr. Atabak Mokari, Chief Financial Officer (Age 42)Ms. Rosemary Y. Williams, Interim Principal Accounting Officer, VP of Fin. & Controller When did Bellicum Pharmaceuticals IPO? (BLCM) raised $101 million in an IPO on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager. Who are Bellicum Pharmaceuticals' major shareholders? Bellicum Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (51.76%), Sumitomo Mitsui Trust Holdings Inc. (4.61%), Nikko Asset Management Americas Inc. (4.61%), Principal Financial Group Inc. (1.01%), ARK Investment Management LLC (0.84%) and Oxford Asset Management LLP (7.06%). Company insiders that own Bellicum Pharmaceuticals stock include Alan A Musso, David M Spencer, Jon P Stonehouse, Richard A Fair and Shane Ward. View Institutional Ownership Trends for Bellicum Pharmaceuticals. Which institutional investors are selling Bellicum Pharmaceuticals stock? BLCM stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., State Street Corp and Renaissance Technologies LLC. View Insider Buying and Selling for Bellicum Pharmaceuticals. Which institutional investors are buying Bellicum Pharmaceuticals stock? BLCM stock was bought by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Principal Financial Group Inc., Oxford Asset Management LLP, ARK Investment Management LLC, Resources Investment Advisors LLC., Raymond James & Associates, UBS Group AG and X Square Capital LLC. Company insiders that have bought Bellicum Pharmaceuticals stock in the last two years include Jon P Stonehouse, Richard A Fair and Shane Ward. View Insider Buying and Selling for Bellicum Pharmaceuticals. How do I buy shares of Bellicum Pharmaceuticals? Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Bellicum Pharmaceuticals' stock price today? One share of BLCM stock can currently be purchased for approximately $10.42. MarketBeat Community Rating for Bellicum Pharmaceuticals (NASDAQ BLCM)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 344 (Vote Outperform)Underperform Votes: 281 (Vote Underperform)Total Votes: 625MarketBeat's community ratings are surveys of what our community members think about Bellicum Pharmaceuticals and other stocks. Vote "Outperform" if you believe BLCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLCM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2020 by MarketBeat.com StaffFeatured Article: What is Cost of Goods Sold (COGS)?
